复方泽桑汤联合胸腺肽 治疗系统性硬皮病的临床疗效观察  

Effect of Zesang Polypharmacy Combined with Thymic Peptide on Treating Systemic Scleroderma

作　　者：徐玉萍[1] 李振鲁[1] 朱钵[1] 

机构地区：[1]河南省人民医院,郑州450003

出　　处：《中国中西医结合皮肤性病学杂志》2012年第2期106-107,共2页Chinese Journal of Dermatovenereology of Integrated Traditional and Western Medicine

摘　　要：目的回顾性分析复方泽桑汤联合胸腺肽治疗系统性硬皮病66例的临床疗效。方法评估复方泽桑汤联合胸腺肽治疗系统性硬皮病66例半年后的疗效。结果痊愈18例(27.3%),显效24例(36.4%),好转20例(30.3%),无效4例(6.1%),有效率为63.64%(42/66)。结论复方泽桑汤联合胸腺肽治疗系统性硬皮病疗效显著。Objective To investigate the effect of Zesang polypharmacy combined with thymic peptide in treating systemic scleroderma（SSc）.Methods 66 patients with SSc were treated with Zesang polypharmacy and thymic peptide for half a year,and than the score was measured to evaluate the treatment effect.Results The effective rate of combined treatment was 63.64%（42/66）.Conclusion Zesang polypharmacy combined with thymic peptide seems to be effective in treating systemic scleroderma.

关 键 词：复方泽桑汤 胸腺肽 系统性硬皮病 

分 类 号：R593.25[医药卫生—内科学]